

Result of General Meeting and Total Voting Rights

Released : March 28, 2022 11:30

RNS Number : 2432G
Destiny Pharma PLC
28 March 2022

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

Destiny Pharma plc
("Destiny" or the "Company")
Result of General Meeting
and
Total Voting Rights

Brighton, United Kingdom - 28 March 2022 - Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, announces that, at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders on a poll.

Accordingly, the Company has raised total gross proceeds of approximately £6.45 million from the Fundraising and has allotted a total of 12,909,007 New Shares. Admission of the 12,909,007 New Shares, comprised of the Placing Shares, the Subscription Shares and the Open Offer Shares, is expected to occur on 29 March 2022.

Following Admission on 29 March 2022, the Company's issued ordinary share capital will comprise 73,307,105 Ordinary Shares, none of which are held in treasury. The above figure of 73,307,0105 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

A summary of the votes received for the General Meeting will be made available on the Company's website at www.destinypharma.com.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 8 March 2022.

Enquiries:

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com

Optimum Strategic Communications

Mary Clark / Hollie Vile / Manel Mateus

+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0)20 7220 0500

MC Services AG (Joint Broker)

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

| | | | |
|----|---|--|-----------|
| 1. | Details of the person discharging managerial responsibilities / person closely associated | | |
| a) | Name | Neil Clark | |
| 2. | Reason for the Notification | | |
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) | Name | Destiny Pharma plc | |
| b) | LEI | 21380009WH9Z38EHAC95 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | |
| a) | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1 pence each ("Ordinary Shares") DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | 50 pence | 50,000 |
| d) | Aggregated information: Aggregated volume Price | See 4c) above | |
| e) | Date of the transaction | 28 March 2022 | |
| f) | Place of the transaction | London Stock Exchange, AIM Market | |

| | | |
|----|---|-------------------------|
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Shaun Claydon |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 21380009WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |

| a) | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1 pence each ("Ordinary Shares") DEST GB00BDHSP575 | | | | | |
|----------|--|--|----------|-----------|----------|--------|--|
| b) | Nature of the transaction | Purchase of Ordinary Shares | | | | | |
| c) | Price(s) and volume(s) | <table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>50 pence</td><td>10,000</td></tr></table> | Price(s) | Volume(s) | 50 pence | 10,000 | |
| Price(s) | Volume(s) | | | | | | |
| 50 pence | 10,000 | | | | | | |
| d) | Aggregated information: Aggregated volume Price | See 4c) above | | | | | |
| e) | Date of the transaction | 28 March 2022 | | | | | |
| f) | Place of the transaction | London Stock Exchange, AIM Market | | | | | |

| 1. | Details of the person discharging managerial responsibilities / person closely associated | | | | | | |
|----------|---|--|----------|-----------|----------|--------|--|
| a) | Name | Nick Rodgers | | | | | |
| 2. | Reason for the Notification | | | | | | |
| a) | Position/status | Chairman | | | | | |
| b) | Initial notification/Amendment | Initial notification | | | | | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | | |
| a) | Name | Destiny Pharma plc | | | | | |
| b) | LEI | 213800O9WH9Z38EHAC95 | | | | | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | | |
| a) | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1 pence each ("Ordinary Shares") DEST GB00BDHSP575 | | | | | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | | | | | |
| c) | Price(s) and volume(s) | <table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>50 pence</td><td>50,000</td></tr></table> | Price(s) | Volume(s) | 50 pence | 50,000 | |
| Price(s) | Volume(s) | | | | | | |
| 50 pence | 50,000 | | | | | | |
| d) | Aggregated information: Aggregated volume Price | See 4c) above | | | | | |
| e) | Date of the transaction | 28 March 2022 | | | | | |
| f) | Place of the transaction | London Stock Exchange. AIM Market | | | | | |

| | | |
|-----------|--|---|
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Debra Barker |
| 2. | Reason for the Notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 1 pence each ("Ordinary Shares") |

| | | | |
|----|---------------------------|-----------------------------------|-----------|
| | Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | 50 pence | 30,000 |
| d) | Aggregated information: | See 4c) above | |
| | Aggregated volume | | |
| | Price | | |
| e) | Date of the transaction | 28 March 2022 | |
| f) | Place of the transaction | London Stock Exchange, AIM Market | |

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRZZGZFGRKGZM